MINNEAPOLIS--(Business Wire)-- AGA Medical Holdings, Inc. (the “Company”) announced the pricing of its initial public offering of 13,750,000 shares of common stock at $14.50 per share. The Company expects to sell 6,509,000 shares, and 7,241,000 shares are expected to be sold by the selling stockholders. The offering is expected to close on October 26, 2009.
The common stock of the Company will be listed on the Nasdaq Global Select Market and will trade under the symbol “AGAM.”
The underwriters have a 30-day option to purchase up to an additional 2,062,500 shares of common stock from the Company to cover overallotments, if any.
BofA Merrill Lynch, Citi, Deutsche Bank Securities, Leerink Swann and Wells Fargo Securities have acted as joint book-running managers for the offering. A copy of the final prospectus relating to these securities may be obtained, when available, from: Merrill Lynch, Pierce, Fenner & Smith Incorporated, 4 World Financial Center, New York, New York 10080, Attention: Preliminary Prospectus Department or by calling 1-866-500-5408; Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220 or by calling 1-800-831-9146; Deutsche Bank Securities Inc., 100 Plaza One, Floor 2, Jersey City, New Jersey 07311-3901 or by calling 1-800-503-4611; Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by calling 1-800-808-7525, Ext. 4814; or Wells Fargo Securities, LLC, Attn: Equity Syndicate Dept., 375 Park Avenue, New York, NY 10152 or by calling 1-800-326-5897.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About AGA Medical Holdings, Inc.
AGA Medical Holdings, Inc., based in Plymouth, Minn., is a leading innovator and manufacturer of medical devices for the treatment of structural heart defects and vascular diseases. Founded in 1995 by Dr. Kurt Amplatz, a former University of Minnesota professor and researcher, AGA Medical`s range of AMPLATZER products help improve patient outcomes, reduce length of hospital stay and accelerate patient recovery times. AMPLATZER products significantly advanced the treatment of the most common congenital “holes in the heart,” such as atrial septal defects, patent foramen ovale and ventricular septal defects. More than 1,500 peer-reviewed articles supporting the benefits of AMPLATZER products have been published in medical literature. AGA Medical markets AMPLATZER products in 112 countries worldwide.
For AGA Medical Holdings:
Nick Banovetz, 612-455-1705
Padilla Speer Beardsley
NBanovetz@psbpr.com
